Drug intelligence / Profile preview

BCT-200

Development stage: Preclinical
Lead developer: Bio-Cancer Treatment International
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
Administration: Intravenous

Overview

BCT-200 is a pegylated recombinant human arginase 1 (pegArg1) developed as an arginine-depleting agent for the treatment of cancers and autoimmune disorders. It is a modified version of BCT-100, designed to maximize drug stability and safety. The mechanism involves enzymatic depletion of extracellular arginine, which targets tumors and immune cells that are auxotrophic for arginine, thereby inhibiting their growth or function. The drug is being developed primarily by Bio-Cancer Treatment International Limited for use in neoplasms (including solid tumors), immune system diseases, and skin/musculoskeletal diseases[1][3][8].

Targets

ARG1 (Arginase 1)

Beyond the preview

Go deeper on BCT-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCT-200.

Explore the full profile